[Form 4] Blueprint Medicines Corporation Insider Trading Activity

Rhea-AI Filing Summary

Blueprint Medicines Corporation (BPMC) – Form 4 filed 23 Jun 2025

Director Lonnel Coats disclosed the award of 3,902 restricted stock units (RSUs) on 18 Jun 2025. Each RSU represents one share of common stock and vests 100 % on the earlier of 18 Jun 2026 or the company’s next annual meeting. No cash consideration was paid; the transaction is coded “A” (acquisition) and reflects routine director compensation rather than an open-market purchase.

Following the grant, Coats’ direct beneficial ownership increased to 6,144 BPMC shares, implying a net addition of 3,902 shares relative to his prior holding. No derivative securities, sales, or additional purchases were reported.

The filing is administrative in nature, providing insight into insider equity alignment but offering no new financial, operational, or strategic information about Blueprint Medicines. Investors may view the added ownership as modestly positive for governance alignment, yet the impact on valuation is likely immaterial.

Positive

• Increased insider alignment: Director’s ownership rises by 3,902 shares, modestly enhancing board-shareholder alignment.

Negative

• No open-market purchase: Grant, not a buy, provides limited confidence signal and no direct cash investment.

Insights

Financial Analyst

TL;DR: Routine RSU grant to director; minimal valuation impact.

The 3,902-share RSU grant increases Coats’ stake to 6,144 shares, signalling continued board-level alignment but without open-market commitment. Because the award is part of standard director compensation and requires no cash outlay, it neither signals confidence through personal investment nor alters the company’s capital structure. Consequently, I view the disclosure as neutral for BPMC’s near-term share price.

Corporate Governance Expert

TL;DR: Governance-aligned equity grant, routine, not materially impactful.

Annual RSU grants help align director incentives with shareholders, satisfying best-practice governance guidelines. Vesting tied to the next annual meeting ensures directors remain engaged, yet the relatively small share count and lack of purchase price limit the signaling value. There are no red flags or preferential terms. Overall, the filing is standard and not impactful beyond routine disclosures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COATS LONNEL

(Last) (First) (Middle)

C/O BLUEPRINT MEDICINES CORPORATION

45 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		3,902(1)	A	$12,812	6,144	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Melissa Masse, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Blueprint Medicines (BPMC) disclose in the 23 Jun 2025 Form 4?

The company reported a grant of 3,902 restricted stock units to Director Lonnel Coats on 18 Jun 2025.

How many BPMC shares does Director Lonnel Coats now own?

After the RSU grant, Coats beneficially owns 6,144 shares of Blueprint Medicines common stock.

When will the granted RSUs vest?

The RSUs vest 100 % on 18 Jun 2026 or at the next annual shareholder meeting, whichever occurs first.

Was an open-market transaction involved?

No. The filing shows an “A” code indicating an acquisition via grant, not an open-market purchase or sale.

Does the Form 4 include any derivative securities?

No derivative securities were reported; only the RSU grant appears in the filing.